Brief: Amylyx Says Phase 3 Trial of Avexitide For Post-Bariatric Hypoglycemia Met Main Goal
18/08/2026 12:00
BRIEF-Amylyx Says Phase 3 Trial of Avexitide For Post-Bariatric Hypoglycemia Met Main Goal Aug 18 (Reuters) - Amylyx Pharmaceuticals, Inc. AMLX.O:
AMYLYX PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 LUCIDITY CLINICAL TRIAL OF AVEXITIDE IN POST-BARIATRIC HYPOGLYCEMIA
AMYLYX PHARMACEUTICALS: LUCIDITY MET FDA-AGREED-UPON PRIMARY ENDPOINT AND ALL SECONDARY ENDPOINTS
AMYLYX PHARMACEUTICALS: AVEXITIDE WAS WELL-TOLERATED WITH A FAVORABLE SAFETY PROFILE
AMYLYX: PLANS TO SUBMIT NDA FOR AVEXITIDE WITH FDA BY YEAR-END & PLANS FOR POTENTIAL LAUNCH IN 2027, IF APPROVED
Further company coverage: AMLX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amylyx Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-LSI Industries, SiTime, Andersen Group
U.S. STOCKS ON THE MOVE-Apple, Hims & Hers Health, Sysco
U.S. STOCKS ON THE MOVE-Nordson, Nebius, Deere
Amylyx dips after increased $500 mln stock sale to fund blood sugar drug
Brief: Amylyx Pharmaceuticals Announces Pricing Of Upsized $500 Million Underwritten Public Offering Of Common Stock